Enterprise Value to EBITDA Ratio: Tempest Therapeutics (TPST)
Tempest Therapeutics (TPST) develops targeted anti-tumor agents, securing long-term revenue through patents and payments from global partners. The market's real-time valuation of the asset at 0.00 accounts for biomaterial logistics complexities and the conduct of tests amidst political fragmentation. Stringent FDA requirements and the capital-intensive nature of development create a robust defensive barrier against new industry entrants.
Analytical breakdowns for tempesttx.com (TPST)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Tempest Therapeutics|TPST - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Tempest Therapeutics, Inc.|TPST - Company Cumulative Debt|Debt to Book Capitalization Ratio Tempest Therapeutics Corp|TPST - Company Long-Term Liabilities|Company Short-Term Debt Tempest Therapeutics|Quick Ratio tempesttx.com
- business earnings and investment ratios data:
TPST - Company Net Income|Expected Profit Tempest Therapeutics|TPST - Business Payback Period|Projected Price to Earnings Tempest Therapeutics|TPST - Company Value to Earnings Growth Ratio|Enterprise Value to EBITDA Ratio Tempest Therapeutics Corp|TPST - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Tempest Therapeutics|TPST - Earnings per share for the last four quarters|Quarterly EPS earnings growth tempesttx.com|TPST - Earnings per share increase in current year|Earnings growth forecast for next year Tempest Therapeutics
Initial company analysis:TPST (Tempest Tx)
Institutional investors utilize this ratio to determine the fair value of Tempest Therapeutics (TPST), accounting for total debt and market capitalization relative to operating cash flow. Analyzing the company's EV/EBITDA ratio over a time series allows for an assessment of the cost efficiency of developing the TPST-1120 drug, where a decrease in the metric confirms the growing fundamental reliability of the asset prior to the commercialization of the oncology therapy.
Competitors of Tempest Therapeutics (TPST)
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to EBITDA Ratio ERAS (Erasca, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio DCTH|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|Aura Biosciences Inc (AURA) - Company Value to EBITDA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray, Inc. (ARAY) - Enterprise Value to EBITDA Ratio|sellaslifesciences.com (SLS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ACTU (actuatetherapeutics.com)|CTOR (Citius Oncology) - EV/EBITDA Multiple|Company Value to EBITDA TuHURA HURA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara (TARA)|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Aadi Bioscience - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan Therapeutics Inc)|CSBR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc.)|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OSTX: Enterprise Value to Operating Income Before Depreciation Ratio|RADX (Radiopharm Theranostics) - EV/EBITDA Multiple|ARTV: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Business Value to Operating Income Before Depreciation RENB|Mural Bio - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|onkuretherapeutics.com (OKUR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Limited)|CRIS (Curis Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Apollomics Corp APLM|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|EV/EBITDA Multiple advanbiomed.com (ADVB)|Genprex - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio CLDI (Calidi Biotherapeutics Inc.)|Sunshine Biopharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Xenetic Biosciences XBIO|SLRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio purple-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CKPT (Checkpoint Therapeutics, Inc)|Enterprise Value to Operating Income Before Depreciation Ratio ELEV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iCAD ICAD|IKNA (Ikena Oncology Inc.) - Company Value to Operating Income Before Depreciation Ratio|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Viracta Therapeutics VIRX|MOR (MorphoSys Corp) - Enterprise Value to EBITDA Ratio|NAYA: Enterprise Value to Operating Income Before Depreciation Ratio|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
